Argenica Therapeutics Completes phase one clinical trial dosing of ARG-007
- Argenica Therapeutics (AGN) completes the dosing stage of a phase one clinical trial of its ARG-007 product to reduce brain tissue death after stroke and injury
- The news marks the completion of Argenica’s fourth and final cohort dosing, which saw six healthy participants dosed with ARG-007 and two receive a placebo
- Throughout the trial, all four doses of the treatment were shown to be well-tolerated by patients, with no serious adverse events observed
- As such, the fourth cohort has been given the tick of approval from the trial’s safety review committee (SRC)
- All trial data will now be compiled and analysed by March 2023 ahead of a final clinical report in May
- ArgenicaTherapeutics shares are up 5.49 per cent to 48 cents at 11:44 am AEDT
